 BOSTON and LAUSANNE, Switzerland, Oct. 12, 2021 PRNewswire -- SOPHiA GENETICS SA Nasdaq: SOPH, the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today the launch of SOPHiA Clinical Exome Solution v3, a new genomic application that offers enhanced probe design and increased detection capabilities for a deeper investigation of Mendelian diseases. SOPHiA Clinical Exome Solution v3 combines a capture-based target enrichment kit with the analytical capabilities and interpretation-support functionalities of the SOPHiA DDMTM platform, offering deep coverage of the target regions and accurate analysis of multiple types of variants SNVs, Indels, and CNVs in one unique experiment. 